Literature summary for 3.2.1.18 extracted from

Fontanella, G.H.; De Vusser, K.; Laroy, W.; Daurelio, L.; Nocito, A.L.; Revelli, S.; Contreras, R.
Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate (2008), Vaccine, 26, 2322-2334.

Search for more literature for 3.2.1.18

Application

Application	Comment	Organism
medicine	mice vaccinated with an engineered enzymatically deficient mutant trans-sialidase containing the catalytic domain without the immunodominant shed acute phase antigen repeats SAPA, are highly protected against Trypanosoma cruzi infection. Adult male BALB/c mice immunized with mutant protein are protected against challenge with a lethal dose of Trypanosoma cruzi trypomastigotes. The protected immunized mice developed no clinical or tissue evidence of infection throughout the study	Trypanosoma cruzi

Cloned(Commentary)

Cloned (Comment)	Organism
expression in Pichia pastoris	Trypanosoma cruzi

Protein Variants

Protein Variants	Comment	Organism
additional information	engineering of an enzymatically deficient mutant trans-sialidase containing the catalytic domain without the immunodominant shed acute phase antigen repeats SAPA. Mice vaccinated with the mutant trans-sialidase are highly protected against Trypanosoma cruzi infection	Trypanosoma cruzi

Organism

Organism	UniProt	Comment	Textmining
Trypanosoma cruzi	-	-	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)